Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
|Articles|October 22, 2012
VIDEO: Robert Frantz, MD, Talks About Bloodstream Infection Rates
Robert Frantz, MD, FACC, Director, Pulmonary Hypertension Clinic, Mayo Clinic, discusses the rate of bloodstream infections in patients with pulmonary arterial hypertension treated with Veletri. Dr Franz also talks about the PROSPECT registry analysis.
Advertisement
Robert Frantz,
MD, FACC, Director, Pulmonary Hypertension Clinic, Mayo Clinic,
discusses the rate of bloodstream infections in patients with pulmonary arterial hypertension treated with Veletri. Dr Franz also talks about the PROSPECT registry analysis.
This video was taken on Sunday, October 21 at the CHEST 2012 conference in Atlanta, GA.
Advertisement
Related to this article
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Data presented at ESMO Congress 2026 show lifileucel met its feasibility end point in refractory sarcoma, with 80% disease control among 10 patients.
Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
4
Real-World Resmetirom Data Look Promising in MASH: Naim Alkhouri, MD
5